MAA
BMY icon

Mraz Amerine & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Mraz Amerine & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,600
Closed -$200K – 166
2022
Q2 		$200K Buy
+2,600
New +$198K 0.05% 151

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mraz Amerine & Associates's BMY Position: Q3 2022 in Review

Mraz Amerine & Associates sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 2,600 shares — an estimated $200K sold.

Mraz Amerine & Associates first reported a position in BMY in Q2 2022 and held it in 1 quarter. The position peaked at $200K in Q2 2022. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

  • Mraz Amerine & Associates reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
  • Mraz Amerine & Associates sold 2,600 Bristol-Myers Squibb shares in Q3 2022, an estimated $200K.
  • Mraz Amerine & Associates first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 1 quarter.
  • Mraz Amerine & Associates's Bristol-Myers Squibb position peaked at $200K in Q2 2022.
  • 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Mraz Amerine & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.